This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.
Otherwise, enjoy the column!
© 2019 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Join our 1,253 Daily Subscribers And Get This FREE Commentary In Your E-Mail!
Roku’s Borrow Rate Rises, plus Biogen, Acadia, Tesla, and Nvidia
The sell-off continued again with the S&P 500 trading down to roughly 2,646, where a sturdy level of support lies. So for now, it looks like we have held, and my guess is that we could have another few points to the downside at most, and I expect that we turn higher again.
Let Michael help you! Have questions? Let Michael help you find the answer. Sign-up and get two weeks free: Watch the latest video: Looking At Twitter
Biotech shares have also found some support around $113.75 on the broader NASDAQ Biotech $IBB ETF. I drew in a downtrend, just because it seems prudent at this point to do so, from the peak at $119.25 to $115.70. The breakout from the past week seems convincing enough to me to think we begin moving higher.
The XBI also failed at resistance, and we have seen a retracement the past couple of days as well. For now, the setup is still bullish, and if the pullback extends to $93.60, it is not the end of the world.
Incyte shares have pulled back too, bringing into question the breakout. But for now, the pullback appears to be a fill the gap scenario more than a then a failed breakout. Tomorrow will be telling.
Regeneron shares have risen, but a big test looms at $352 with an intense level of resistance waiting, my guess resistance holds, and the stock moves lower.
Acadia shares fell hard in recent days but have held support at around $25, and I think that means shares could be headed back towards $26.5. My hunch or gut feeling, as we approach the depression data later this fall, we may see some buyers or traders looking to cover short ahead of the news, and that could help to lift the price. Short Interest stood at roughly 10.3 million as of February 28.
Biogen shares also started to bounce a bit too. It would be a positive should this stock start rising again for the group.
Roku’s borrow rate continues to surge, according to TradeAlert, the rate is over 100 percent. Insane.
In fact, we can also see the implied volatility levels on the options are rising the further into the future one goes. It would suggest that traders are betting on the volatility in the stock to continuing rising, and thus the risk in the stock is rising as well.
As of the February 28, short-interest surged to 9.946 million shares, representing 63.5 percent of the float! That is massive!
AMD shares are entering a danger zone, with the stock moving towards the cusp of a breakdown. The $11.20 technical support significant, a break below send the price towards the $10.50 region.
In the latest round of Tesla drama, CNBC is reporting that the company is churning out flawed parts. When I saw this, I was like “is the old news or new news?” That is right it was just at the end of January they reported batteries were being put together by hand.
I’m not sure what the delivery rates or how batteries are being assembled, I’m not even sure today’s news is even new? It sounds a lot like old news. But it doesn’t matter because the stock went down as a result.
Somebody made a big bet share would fall to about $250 bucks today, with the purchase of about 4,000 contracts of the April $250 puts. The notional value is only about $500k. Not huge, but undoubtedly interesting.
Today was RBC’s turn to raise its price target on NVIDIA, by an astonishing $5 to $285, talk about sticking your neck out there. But what I find interest is that price adjustment comes despite Nvidia potentially facing a notable slowdown in cryptocurrency benefits. But of course, they see a scenario of $12+ in earnings per share by the year the year 2021, on data center and gaming! That is nearly $2.50 ABOVE consensus of $9.50 per share. So why only give the stock 15 percent upside, if you are looking for earning to come in 26% higher than consensus. I don’t know. Sorry, I don’t get it.
Until Tomorrow! Good Luck!
Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets
Free Articles Written By Mike:
Join our 1,253 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe
[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]
Michael Kramer and the clients of Mott Capital own shares of ACAD, TSLA
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.
© 2018 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.
Tags: #sp500 #technology #roku #tesla #nvidia #biotech #biogen #incyte #acadia